On September 2, 2025, Mineralys Therapeutics announced the commencement of an underwritten public offering of $175.0 million of its common stock. The company also expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares.
All securities in the offering are to be sold by Mineralys, with the net proceeds intended to fund the clinical development of lorundrostat, including research and development and manufacturing. Funds will also support pre-commercialization activities, working capital, and general corporate purposes.
This financing initiative is critical for a clinical-stage biopharmaceutical company to ensure sufficient capital for advancing its lead product candidate through regulatory processes and preparing for potential market entry. The offering is subject to market and other conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.